Demand for weight-loss medicines in the UK has run well ahead of what the NHS can provide. Researchers at UCL estimate that 1.6 million adults in Great Britain used a medicine to lose weight between early 2024 and early 2025, and that a further 3.3 million were interested in doing so [1]. NHS England began funding tirzepatide in primary care in June 2025 for around 220,000 people over the first three years [2], against the 3.4 million people in England that NICE considers eligible [3]. The rest of that GLP-1 demand is being met through private services, many of them online [4].
Retailers know what a sudden surge in demand does to a business. It tests everything behind the storefront: whether stock, orders, payments and customer service are working from the same information, and whether the systems underneath can change as quickly as the market does. Healthcare is now facing the same test, but with far less room for error. For anyone responsible for digital services in the sector, the most important lesson of rising GLP-1 demand is what it’s revealed about the infrastructure underneath.
A channel with many hands on it
In the US, several large drugmakers have built direct-to-patient sales channels over the past couple of years, but the UK route to treatment looks very different. GLP-1 medicines are prescription-only, so patients can only obtain them from a registered pharmacy with a prescription [5], and manufacturers are prohibited by law from shipping prescription-only medicines directly to patients [6]. When one US manufacturer brought its patient service to the UK in June 2026, it launched as a post-prescription dispensing and delivery service, working through regulated prescribers and partner pharmacies [6]. All of which means that the patient’s experience is put together across several organisations, each with its own systems.
That arrangement is under visible strain. The General Pharmaceutical Council’s review of weight-management services, published in April 2026, counted 1,307 concerns in Great Britain across 2024 and 2025, and 1,099 of them came in the second year [4]. Several of the examples it gives describe information that failed to travel between organisations, such as GPs being told about prescriptions but with the dose left out, a GP never being informed despite the patient’s consent, and clinical records being sent to a retired GP.
GLP-1 demand and the work behind the screen
When digital demand rises, the instinct is to invest in things that people can see, like a new website, an app, or a smoother consultation flow, but retailers followed that instinct for years and found its limits. A nicely polished storefront doesn’t achieve much when the catalogue, stock levels, pricing, orders and customer service each hold their own version of the truth, and when a change that looks simple on the page takes months to deliver behind it.
The retailers that handle demand well are the ones that spent the past decade connecting those systems. Many of them moved away from the idea that every capability should sit inside one large platform and adopted headless, API-first and modular architectures instead. The experience that customers see is separated from the services that power it, and each service can be adjusted and changed on its own. That separation is what lets a retailer add a delivery option, a payment method or a new sales channel quickly, without reopening and reconfiguring everything else.
Healthcare needs the same connective work, but with higher stakes. Connected systems can make it easier to ensure required checks are built into workflows, the necessary information reaches the right people, in the right order, and clear records are kept. Every step in prescribing and dispensing stays where it is, but what connected systems change is how reliably each step happens and how much time clinical and pharmacy teams lose to re-keying and chasing information.
It’s also worth pointing out that the way retailers made that change matters just as much as the destination. The ones that did it well rarely replaced everything at once. They found the points where information broke down, connected new capabilities to the systems they already had, and built out from there. Healthcare organisations can take the same approach, avoiding the years of disruption that come with a single, all-encompassing transformation programme.
Built for the next change
The pace of change in this market makes that flexibility essential. In June 2026 the MHRA approved the UK’s first GLP-1 tablet for weight management, with its own fasting and dosing instructions and a route for some patients to switch from weekly injections to a daily tablet [7]. Within a week, regulators warned businesses against promoting newly licensed oral treatments, including through waiting lists [8]. In August a second tablet was authorised, this time with no food or water restrictions [5]. Each of those developments affected patient information, dosing schedules, the checks before supply and what a business was allowed to say in public.
When requirements like these are hard-coded into a single large system, every change becomes a project to reopen the whole thing, with all the risk and testing that come with it. But when the clinical checks, consultation records, dispensing hand-offs and patient communications are all separate components with clear connections between them, a team can update one and test it properly while simultaneously keeping everything else running.
Governance designed in
In healthcare, flexibility only works if control comes with it. Auditability, clear ownership of each step and a full record of every clinical decision need to be baked into the architecture from the start, where they can be seen and tested. The GPhC’s own recommendations [4] point the same way, calling for documented risk assessments, due diligence on third-party prescribing services and thorough records of every consultation and decision. The same discipline applies to content. A system that governs what can appear where is better placed to stay within the advertising rules than a team checking pages by hand.
GLP-1 medicines won’t be the last treatment to change how and where people seek care. The scale of GLP-1 demand has exposed what happens when consumer need moves faster than the systems designed to serve it. Healthcare organisations that build connected, adaptable foundations now, with governance designed in from the start, will be ready for whatever comes next, able to give patients the digital experience they now expect with the control the sector will always need.
Author Bio
